PO.TB09.02 · 肿瘤生物学
人类肾单位的克隆图谱
Clonal landscape of human nephrons
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:肾细胞癌(RCC)亚型被认为起源于不同的肾单位节段,这提示正常肾单位中遗传改变的累积和模式也可能因节段而异。然而,由于其复杂的结构以及单独分离各肾单位节段的技术挑战,肾单位内的突变图谱仍知之甚少。
方法:我们采用激光捕获显微切割(LCM)分离五个不同的肾单位节段,包括近端曲小管和直小管(PCT和PST)、远端曲小管和直小管(DCT和DST)以及集合管(CD),随后使用高精度测序平台(NanoSeq)和全外显子组测序(WES)进行分析。
结果:对来自12例患者的175份LCM样本进行NanoSeq分析显示,单核苷酸变异(SNV)随年龄增长呈线性增加。然而,累积速率在各节段间差异显著:PCT和PST显示出明显更高的速率(分别为每基因组每年123和132个SNV),而DST(28)、DCT(27)较低,CD最低(18)。检测到七种SBS特征(SBS1、5、8、12、40a-c)。与年龄相关的SBS5在所有节段间相似,并占远端区室大部分突变。相比之下,SBS12、SBS40b和SBS40c主要局限于近端节段,很大程度上解释了其较高的突变负荷。此外,SBS12特征在PCT中显著富集,表现出强烈的转录链偏倚。对来自6例患者的683份LCM样本进行的WES分析显示,老年供者的近端小管和CD中频繁发生单克隆扩增,而在远端小管中罕见。值得注意的是,在形态学正常的PCT中观察到一个广泛扩增的克隆,其携带3p缺失和影响PBRM1(透明细胞RCC中常见的驱动基因)的突变。总体而言,所有LCM样本中有11.7%携带≥1个影响已知RCC驱动基因的非同义突变。这些突变大多在近端小管中检测到,而在远端小管和CD中罕见。拷贝数改变相当常见,见于35.1%的样本,并与供者年龄强相关。最常见的改变包括10号和7号染色体的获得以及18号和22号染色体的缺失。值得注意的是,10号染色体获得主要局限于近端肾单位,而18号染色体缺失几乎仅见于CD。
结论:老化的肾单位经历显著的重塑,其特征是节段特异性的突变累积和克隆扩增。近端小管表现出最高的突变率并累积RCC驱动改变。SBS12特征在PCT中的强烈富集证实了先前认为PCT是该RCC亚型起源的观点。SBS12的强链偏倚提示从PCT吸收的外源性致突变物的影响,识别致病因子对RCC预防可能具有重要意义。
查看英文原文 English abstract
Background: Renal cell carcinoma (RCC) subtypes are believed to arise from distinct nephron segments, suggesting that the accumulation and patterns of genetic alterations in normal nephron may also vary by segment. However, due to the intricate architecture and the technical challenges in isolating each nephron segment separately, the mutational landscape within the nephrons remains poorly understood.
Methods: We used laser-capture microdissection (LCM) to isolate five distinct nephron segments, including proximal convoluted and straight tubules (PCT and PST), distal convoluted and straight tubules (DCT and DST), and collecting ducts (CD), which were then analyzed using a highly accurate sequencing platform (NanoSeq) and whole exome sequencing (WES).
Results: NanoSeq analysis of the 175 LCM samples from 12 patients revealed that single nucleotide variants (SNVs) linearly increased with aging. However, the accumulation rate markedly varied across segments: PCT and PST showed notably higher rates (123 and 132 SNVs per genome/year, respectively), compared with DST (28), DCT (27), and the lowest in CDs (18). Seven SBS signatures (SBS1,5,8,12,40a-c) were detected. The age-related SBS5 was similar across all segments and accounted for most of the mutations in the distal compartments. In contrast, SBS12, SBS40b and SBS40c were largely confined to the proximal segments, mostly explaining their higher mutational burdens. Furthermore, the SBS12 signature was significantly enriched in PCT, showing a strong transcriptional strand bias. WES analyses on the 683 LCM samples from 6 patients showed frequent monoclonal expansion in the proximal tubules and CDs of aged donors, which were rarely seen in distal tubules. Notably, an extensively expanded clone in the PCT harboring a 3p loss and a mutation affecting PBRM1, a common driver gene in clear cell RCC, was observed in morphologically normal PCTs. In total, 11.7% of all LCM samples harbored ≥1 non-synonymous mutations affecting known RCC driver genes. Most of these mutations were detected in proximal tubules, while rarely found in distal tubules and CDs. Copy number alterations were quite common, found in 35.1% of the samples and strongly correlated with donor age. The most frequent alterations included gains of Chromosomes 10 and 7 and losses of Chromosomes 18 and 22. Of note, chromosome 10 gain was mostly confined to proximal nephrons, while Chromosome 18 loss was almost exclusively found in CD.
Conclusion: Aging kidney nephrons undergo pronounced remodeling characterized by segment-specific accumulation of mutations and clonal expansions. Proximal tubules exhibit the highest mutation rates and accumulate RCC driver alterations. The strong enrichment of the SBS12 signature in the PCT confirmed the previous view that PCT is the origin of this RCC subtype. The strong strand bias for SBS12 suggests the influence of exogenous mutagens absorbed from PCTs, and identifying the causative agent could be important for RCC prevention.
利益披露 Disclosure
K. Ieiri,
Nanpu hospital Other, Belonging to an Endowed Department.
N. Kakiuchi, None..
K. Watananbe, None..
T. Hirano, None..
S. Kawaguchi, None..
H. Maeda, None..
Y. Inoue, None..
T. R. Kataoka, None..
H. Tanaka, None..
S. Miyano, None..
M. Shiota, None..
E. Masatoshi, None.
S. Ogawa,
KAN Research Institute, Inc. Employment.
ChordiaTherapeutics, Inc. Employment.
Asahi Genomics Co., Ltd. Stock.
Sumitomo Dainippon Pharma Co., Ltd. ).
Otsuka Pharmaceutical Co., Ltd. ).
Eisai Co., Ltd. ).